New England Journal of Medicine· 2016Q1
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
- 3,340citations
- Q1SCImago
- 2016year
Short summary
Osimertinib significantly improved progression-free survival (10.1 vs. 4.4 months) and objective response rate (71% vs. 31%) compared to platinum-pemetrexed in patients with T790M-positive advanced non-small-cell lung cancer who progressed on prior EGFR-TKI therapy.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine